Presentations
November 6, 2023
A Phase 2 Trial of Belzupacap Sarotalocan, a Targeted Investigational Therapy for Choroidal Melanoma via Suprachoroidal Administration
April 24, 2023
A novel immunotherapy for the treatment of HPV+ tumors based on a chimeric Virus-like Drug Conjugate
April 24, 2023
A novel chimeric virus-like drug conjugate for the potential treatment of HPV+ tumors
April 24, 2023
The role of pigmentation in tumor treatment with virus-like drug conjugate belzupacap sarotalocan (AU-011) in an vitro and vivo model
February 16, 2023
A Phase 2 Trial of Belzupacap Sarotalocan (AU-011): An Investigational Targeted Therapy for Choroidal Melanoma via Suprachoroidal Administration
November 30, 2022
A Phase 1, Open-Label Trial to Determine Feasibility and Safety of Intramural Injection of Belzupacap Sarotalocan (AU-011) in Non-Muscle Invasive Bladder Cancer (NMIBC)
October 3, 2022
A Phase 2 Trial of Belzupacap Sarotalocan (AU-011), a First-in-Class Targeted Therapy for Choroidal Melanoma via Suprachoroidal Administration
September 10, 2022
A Phase 2 Trial of Belzupacap Sarotalocan (AU-011), an Investigational, Virus-Like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma ...
September 3, 2022
New Developments in Belzupacap Sarotalocan (AU-011), an Investigational Virus-Like Drug Conjugate (VDC) in Ocular Oncology
September 2, 2022
Clinical Evaluation of Belzupacap Sarotalocan (AU-011), a First-in-Class Targeted Therapy for Choroidal Melanoma with Intravitreal or Suprachoroidal Route of Administration
June 22, 2022
Topline Data from a Retrospective, Matched Case Study Evaluating Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy, Supports the Value of a Vision Preserving Therapy for the ...
June 20, 2022
A Phase 2 Trial of belzupacap sarotalocan (AU-011), a First-in-class Targeted Therapy for Choroidal Melanoma via Suprachoroidal (SC) Administration
June 20, 2022
A Phase 1b/2 Trial of belzupacap sarotalocan (AU-011), a First-in-Class Targeted Therapy for the Treatment of Choroidal Melanoma via Intravitreal Administration
May 3, 2022
A First in Class Virus-Like Drug Conjugate (VDC) Shows Anti-tumor Activity in Cancers that Commonly Metastasize to the Choroid
April 8, 2022
Biological assessment of the virus-like drug conjugate AU-011 to specifically target a breadth of human cancer types
February 14, 2022
Targeting urothelial neoplasia using an investigational virus-like drug conjugate
November 15, 2021
A Phase 1b/2 Trial of AU-011, an Investigational, Virus-Like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL/CM) using ...
November 15, 2021
A Phase 2 Trial of AU-011, an Investigational, Virus-Like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL/CM) using ...
October 11, 2021
A Phase 2 Trial of AU-011, an Investigational, Virus-Like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL/CM) using ...
September 13, 2021
A Phase 2 Trial of AU-011for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma using Suprachoroidal Administration
May 5, 2021
Development of AU-011 for Choroidal Metastasis
May 2, 2021
Ocular Distribution and Exposure of AU-011 After Suprachoroidal or Intravitreal Administration in an Orthotopic Rabbit Model of Human Uveal Melanoma
November 10, 2020
AU-011, a Targeted Therapy for Primary Treatment of Choroidal Melanoma (CM) via Intravitreal (IVT) or Suprachoroidal (SC) Administration
June 12, 2020
Ocular Distribution and Efficacy After Suprachoroidal Injection of AU-011 for Treatment of Ocular Melanoma” – Presented at AVRO 2020
June 12, 2020
An Ongoing Phase 1B/2 Open-Label Clinical Trial to Evaluate the Safety and Efficacy of AU-011 for the Treatment of Choroidal Melanoma – Study Update” – Presented at ARVO 2020